GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for topical ocular reproxalap, a first-in-cla ...